SCHEMBL22018637

SCHEMBL22018637

CC(C)CCCCCCCNC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
HRH4 Q9H3N8 2/20 0.37
HRH3 Q9Y5N1 2/20 0.37
KDM4C Q9H3R0 2/20 0.32
KDM4A O75164 1/20 0.32
PHF8 Q9UPP1 1/20 0.32
KDM2A Q9Y2K7 1/20 0.32
TP53BP1 Q12888 1/20 0.31
POLB P06746 1/20 0.31
MEN1 O00255 1/20 0.31
CYP3A4 P08684 1/20 0.31
ALOX15 P16050 1/20 0.31
KMT2A Q03164 1/20 0.31
EPHX1 P07099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24031315 1.00 LMNA (0.40) LMNAHRH4HRH3KDM4CKDM4A
SCHEMBL20349749 1.00 LMNA (0.40) LMNAHRH4HRH3KDM4CKDM4A
SCHEMBL18820323 1.00 LMNA (0.40) LMNAHRH4HRH3KDM4CKDM4A
SCHEMBL23696194 1.00 LMNA (0.40) LMNAHRH4HRH3KDM4CKDM4A
SCHEMBL15745492 0.98 LMNA (0.42) LMNAHRH4HRH3TP53BP1POLB
SCHEMBL12016491 0.90 LMNA (0.38) LMNAHRH4HRH3TP53BP1MEN1
SCHEMBL19750419 0.85 CYP2C19 (0.36) HRH4HRH3MEN1KMT2A
SCHEMBL23696555 0.85 CYP2C19 (0.36) HRH4HRH3MEN1KMT2A
SCHEMBL24950430 0.84 POLB (0.36) HRH4HRH3POLB
SCHEMBL21341869 0.82 HRH4 (0.35) HRH4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 US disclosed
US-10660968-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11185592-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A LMNA 1938/4885HRH4 4475/4885HRH3 4489/4885
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A LMNA 1938/4885HRH4 4475/4885HRH3 4489/4885
US-10660968-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A LMNA 1938/4885HRH4 4475/4885HRH3 4489/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 LMNA 1656/4885HRH4 3886/4885HRH3 3631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.